Ankylosing
spondylitis is an idiopathic disease, associated with HLA-B27, IL23R and ERAP1
genes. Usually, fewer people get affected with ankylosing spondylitis
irrespective of activation of genes. Blood test, X-ray test, Magnetic Resonance
Imaging (MRI) and physical investigations are some of the ways to effectively diagnose
the disease. The disease begins with the inflammation in joints in the
vertebrae and pelvic bones and spine. The environmental factors are believed to
be the most important risk factor for increasing the incidence of the disease.
The primary symptoms include back pain and stiffness.
Explore Report at: https://www.psmarketresearch.com/market-analysis/ankylosing-spondylitis-therapeutics-pipeline-analysis
Considerable
growth in therapeutic pipeline of ankylosing spondylitis is attributed to the
increase in prevalence of the disease among teens as well as young adult
patients. Researchers have not been able to identify the actual cause of the
disease. Novel anti-inflammatory agents and pain killers are being developed
that are primarily responsible for the growth of therapeutics pipeline for
ankylosing spondylitis.
In
June 2015, UniQuest Pty Ltd signed a collaborative agreement with Janssen Cilag
Pty Limited for development and commercialization of small molecule modulators
of a biological target identified by the University of Queensland, as an
important factor for the treatment of ankylosing spondylitis, and potentially
psoriasis and inflammatory bowel disease. In December 2016, Janssen Biotech,
Inc. confirmed the submission of two Supplemental Biologics License
Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking
approval of SIMPONI ARIA (golimumab) for the treatment of patients with psoriatic
arthritis as well as ankylosing spondylitis. SIMPONI ARIA is fully humanised
anti-tumour necrosis factor alpha therapy.
Some of the companies having a pipeline of ankylosing spondylitis therapeutics include, AbbVie Inc., Sanofi SA, Centocor Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Janssen Research & Development, LLC, Novartis AG, Amgen plc, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corp., Galapagos NV, Celgene Corporation, Shanghai Pharmaceuticals Holding Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Pfizer Inc., UCB Pharma SA, Eli Lilly and Company, Eisai Co., Ltd., Korea Otsuka Pharmaceutical Co., Ltd., Inflexxion Inc. and Johnson & Johnson Pvt. Ltd.
No comments:
Post a Comment